Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
How Human iPSCs are Revolutionizing Drug Discovery in 2025
Drug discovery involves high cost and uncertain outcomes. Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerge during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.
Thankfully, some new medicines are now being tested for safety on specialized cells developed from human pluripotent cell lines. Cell types which are increasingly being used within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]
The Role of iPSCs in Farm Animals and Wildlife Conservation
Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have been potently transforming regenerative medicine, biotechnology, and conservation. Their ability to be reprogrammed from adult somatic cells unlocks new possibilities for enhancing farm animal reproduction, boosting disease resistance, and improving food quality, while also playing a pivotal role in wildlife conservation and species revival. However, their use raises ethical concerns, including the risks of genetic modification, unforeseen ecological consequences, and the moral dilemmas surrounding species de-extinction. [Read more…]
Cellino and Matricelf Collaborate to Scale iPSC-Derived Treatments for Spinal Cord Injury (SCI)
Cellino successfully manufactures and delivers autologous iPSC lines from four donors to Matricelf for groundbreaking neural tissue engineering.
Matricelf transformed Cellino-generated iPSCs into functional neural tissues with synchronized electrical activity.
CAMBRIDGE, Mass. – Cellino and Matricelf (TASE: MTLF) announced a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebula™ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies. [Read more…]
REPROCELL’s Clinical-Grade iPSCs:
Advancing Cell Therapy
In the rapidly evolving field of regenerative medicine, REPROCELL’s StemRNATM Clinical iPSCs provide a benchmark for clinical grade induced pluripotent stem cells (iPSCs). These high-quality iPSCs provide a foundation for various cell therapy programs, ensuring safety, consistency, and regulatory compliance. Our clinical iPSCs are currently being evaluated by many biopharma companies globally, are selected for regulatory filings and are IND approved. REPROCELL is a trusted partner for cell therapy developers who are seeking robust, high-quality clinical iPSC banks that meet industry standards. [Read more…]
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 78
- Next Page »